Literature DB >> 21511863

Percentage signal recovery derived from MR dynamic susceptibility contrast imaging is useful to differentiate common enhancing malignant lesions of the brain.

R Mangla1, B Kolar, T Zhu, J Zhong, J Almast, S Ekholm.   

Abstract

BACKGROUND AND
PURPOSE: Differentiation of enhancing malignant lesions on conventional MR imaging can be difficult and various newer imaging techniques have been suggested. Our aim was to evaluate the role of PSR obtained from DSC perfusion measurements in differentiating lymphoma, GBM, and metastases. The effectiveness of PSR was compared with that of rCBV. We hypothesized that the newly defined parameter of PSR is more sensitive and specific in differentiating these lesions.
MATERIALS AND METHODS: This retrospective study included 66 patients (39 men and 27 women; age range: 27-82 years) with a pathologically proved diagnosis of primary CNS lymphoma, GBM, or metastases (22 patients in each group). Mean PSR, min PSR, max PSR, and rCBV were calculated. The classification accuracy of these parameters was investigated by using ROC.
RESULTS: Mean PSR was high (113.15 ± 41.59) in lymphoma, intermediate in GBM (78.22 ± 14.27), and low in metastases (53.46 ± 12.87) with a P value < .000. F values obtained from 1-way ANOVA analysis for mean, min, and max PSR ratios were 29.9, 39.4, and 23.4, respectively, which were better than those of rCBV (11.1) in differentiating the 3 groups. Max PSR yielded the best ROC characteristics with an A(z) of 0.934 (95% CI, 0.877-0.99) in differentiating lymphoma from metastases and GBM. The A(z) for mean and min PSR of 0.938 (95% CI, 0.0.884-0.990) and 0.938 (95% CI, 0.884-0.991), respectively, was better than rCBV (A(z), 0.534; 95% CI, 0.391-0.676) in the differentiation of metastases from GBM and lymphoma (P ≤ .0001).
CONCLUSIONS: PSR appears to be a parameter that helps in differentiating intracerebral malignant lesions such as GBM, metastases, and lymphoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21511863      PMCID: PMC8013151          DOI: 10.3174/ajnr.A2441

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  30 in total

1.  High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging.

Authors:  Meng Law; Soonmee Cha; Edmond A Knopp; Glyn Johnson; John Arnett; Andrew W Litt
Journal:  Radiology       Date:  2002-03       Impact factor: 11.105

2.  Diagnostic delay in primary central nervous system lymphoma.

Authors:  Ingfrid S Haldorsen; Ansgar Espeland; John Ludvig Larsen; Olav Mella
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

3.  Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors.

Authors:  Eric S Paulson; Kathleen M Schmainda
Journal:  Radiology       Date:  2008-09-09       Impact factor: 11.105

4.  Meningiomas with conventional MRI findings resembling intraaxial tumors: can perfusion-weighted MRI be helpful in differentiation?

Authors:  Bahattin Hakyemez; Nalan Yildirim; Cüneyt Erdoğan; Hasan Kocaeli; Ender Korfali; Mufit Parlak
Journal:  Neuroradiology       Date:  2006-08-01       Impact factor: 2.804

5.  Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors.

Authors:  M A Weber; S Zoubaa; M Schlieter; E Jüttler; H B Huttner; K Geletneky; C Ittrich; M P Lichy; A Kroll; J Debus; F L Giesel; M Hartmann; M Essig
Journal:  Neurology       Date:  2006-06-27       Impact factor: 9.910

6.  Capillary ultrastructure in human metastatic brain tumors.

Authors:  D M Long
Journal:  J Neurosurg       Date:  1979-07       Impact factor: 5.115

Review 7.  Diffusion and perfusion magnetic resonance imaging in brain tumors.

Authors:  D Le Bihan; P Douek; M Argyropoulou; R Turner; N Patronas; M Fulham
Journal:  Top Magn Reson Imaging       Date:  1993

8.  Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction.

Authors:  R Haselhorst; L Kappos; D Bilecen; K Scheffler; D Möri; E W Radü; J Seelig
Journal:  J Magn Reson Imaging       Date:  2000-05       Impact factor: 4.813

9.  Single Brain Metastasis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2001-01       Impact factor: 3.598

10.  Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.

Authors:  Weihua Liao; Yunhai Liu; Xiaoyi Wang; Xinya Jiang; Beisha Tang; Jiasheng Fang; Changqing Chen; Zhongliang Hu
Journal:  Acta Radiol       Date:  2009-03       Impact factor: 1.990

View more
  50 in total

1.  Diagnostic accuracy of dynamic contrast-enhanced MR imaging using a phase-derived vascular input function in the preoperative grading of gliomas.

Authors:  T B Nguyen; G O Cron; J F Mercier; C Foottit; C H Torres; S Chakraborty; J Woulfe; G H Jansen; J M Caudrelier; J Sinclair; M J Hogan; R E Thornhill; I G Cameron
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-22       Impact factor: 3.825

Review 2.  Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumours.

Authors:  Ananya Chakravorty; Timothy Steel; Joga Chaganti
Journal:  Neuroradiol J       Date:  2015-10-16

Review 3.  Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.

Authors:  P D Delgado-López; E Riñones-Mena; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2017-12-07       Impact factor: 3.405

4.  Perfusion magnetic resonance imaging in pediatric brain tumors.

Authors:  F Dallery; R Bouzerar; D Michel; C Attencourt; V Promelle; J Peltier; J M Constans; O Balédent; C Gondry-Jouet
Journal:  Neuroradiology       Date:  2017-08-31       Impact factor: 2.804

5.  High- and low-grade glioma differentiation: the role of percentage signal recovery evaluation in MR dynamic susceptibility contrast imaging.

Authors:  Italo Aprile; Giorgia Giovannelli; Paola Fiaschini; Marco Muti; Anna Kouleridou; Nevia Caputo
Journal:  Radiol Med       Date:  2015-03-12       Impact factor: 3.469

6.  Differentiation of hemangioblastomas from pilocytic astrocytomas using 3-T magnetic resonance perfusion-weighted imaging and MR spectroscopy.

Authors:  D J She; Z Xing; Z Zeng; X Y Shang; D R Cao
Journal:  Neuroradiology       Date:  2014-12-07       Impact factor: 2.804

Review 7.  MR imaging of brain pilocytic astrocytoma: beyond the stereotype of benign astrocytoma.

Authors:  Simona Gaudino; Matia Martucci; Rosellina Russo; Emiliano Visconti; Emma Gangemi; Francesco D'Argento; Tommaso Verdolotti; Libero Lauriola; Cesare Colosimo
Journal:  Childs Nerv Syst       Date:  2016-10-18       Impact factor: 1.475

8.  Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.

Authors:  M D Lee; G L Baird; L C Bell; C C Quarles; J L Boxerman
Journal:  AJNR Am J Neuroradiol       Date:  2019-08-01       Impact factor: 3.825

9.  Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patients.

Authors:  Vaios Hatzoglou; Gary A Ulaner; Zhigang Zhang; Kathryn Beal; Andrei I Holodny; Robert J Young
Journal:  Clin Imaging       Date:  2012-10-12       Impact factor: 1.605

10.  MRI perfusion in determining pseudoprogression in patients with glioblastoma.

Authors:  Robert J Young; Ajay Gupta; Akash D Shah; Jerome J Graber; Timothy A Chan; Zhigang Zhang; Weiji Shi; Kathryn Beal; Antonio M Omuro
Journal:  Clin Imaging       Date:  2012-06-08       Impact factor: 1.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.